Managed Care - September 2008 - (Page 29) treatment and consider tapering Effexor XR in the third trimester. Labor, Delivery, Nursing—The effect on labor and delivery in humans is unknown. Venlafaxine and ODV have been reported to be excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from Effexor XR, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use—Safety and effectiveness in the pediatric population have not been established (see BOX WARNING and WARNINGS: Clinical Worsening and Suicide Risk). No studies have adequately assessed the impact of Effexor XR on growth, development, and maturation of children and adolescents. Studies suggest Effexor XR may adversely affect weight and height (see PRECAUTIONS-General, Changes in Height and Changes in Weight ). Should the decision be made to treat a pediatric patient with Effexor XR, regular monitoring of weight and height is recommended during treatment, particularly if long term. The safety of Effexor XR for pediatric patients has not been assessed for chronic treatment >6 months. In studies in patients aged 6-17, blood pressure and cholesterol increases considered to be clinically relevant were similar to that observed in adult patients. The precautions for adults apply to pediatric patients. Geriatric Use—No overall differences in effectiveness or safety were observed between geriatric and younger patients. Greater sensitivity of some older individuals cannot be ruled out. SSRIs and SNRIs, including Effexor XR, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event (see PRECAUTIONS: Hyponatremia). ADVERSE REACTIONS: Associated with Discontinuation of Treatment— The most common events leading to discontinuation in MDD, GAD, SAD, and PD trials included nausea, anorexia, anxiety, impotence, dry mouth, dizziness, insomnia, somnolence, hypertension, diarrhea, paresthesia, tremor, abnormal (mostly blurred) vision, abnormal (mostly delayed) ejaculation, asthenia, vomiting, nervousness, headache, vasodilatation, thinking abnormal, decreased libido, and sweating. Commonly Observed Adverse Events in Controlled Clinical Trials for MDD, GAD, SAD, and PD—Body as a Whole: asthenia, headache, flu syndrome, accidental injury, abdominal pain. Cardiovascular: vasodilatation, hypertension, palpitation. Digestive: nausea, constipation, anorexia, vomiting, flatulence, diarrhea, eructation. Metabolic/Nutritional: weight loss. Nervous System: dizziness, somnolence, insomnia, dry mouth, nervousness, abnormal dreams, tremor, depression, hypertonia, paresthesia, libido decreased, agitation, anxiety, twitching. Respiratory System: pharyngitis, yawn, sinusitis. Skin: sweating. Special Senses: abnormal vision. Urogenital System: abnormal ejaculation, impotence, orgasmic dysfunction (including anorgasmia) in females. Vital Sign Changes: Effexor XR was associated with a mean increase in pulse rate of about 2 beats/min in depression and GAD trials and a mean increase in pulse rate of 3 beats/min in SAD trials. (see Sustained Hypertension and Elevations in Systolic and Diastolic Blood Pressure sections of WARNINGS). Laboratory Changes: Clinically relevant increases in serum cholesterol were noted in Effexor XR clinical trials. Increases were duration dependent over the study period and tended to be greater with higher doses. Other Events Observed During the Premarketing Evaluation of Effexor and Effexor XR —N=7,212. “Frequent”=events occurring in at least 1/100 patients; “infrequent”=1/100 to 1/1000 patients; “rare”=fewer than 1/1000 patients. Body as a whole - Frequent: chest pain substernal, chills, fever, neck pain; Infrequent: face edema, intentional injury, malaise, moniliasis, neck rigidity, pelvic pain, photosensitivity reaction, suicide attempt, withdrawal syndrome; Rare: appendicitis, bacteremia, carcinoma, cellulitis, granuloma. Cardiovascular system - Frequent: migraine, tachycardia; Infrequent: angina pectoris, arrhythmia, extrasystoles, hypotension, peripheral vascular disorder (mainly cold feet and/or cold hands), postular hypotension, syncope; Rare: aortic aneurysm, arteritis, first-degree atrioventricular block, bigeminy, bundle branch block, capillary fragility, cerebral ischemia, coronary artery disease, congestive heart failure, heart arrest, hematoma, cardiovascular disorder (mitral valve and circulatory disturbance), mucocutaneous hemorrhage, myocardial infarct, pallor, sinus arrhythmia, thrombophlebitis. Digestive system - Frequent: increased appetite; Infrequent: bruxism, colitis, dysphagia, tongue edema, eructation, esophagitis, gastritis, gastroenteritis, gastrointestinal ulcer, gingivitis, glossitis, rectal hemorrhage, hemorrhoids, melena, oral moniliasis, stomatitis, mouth ulceration; Rare: abdominal distension, biliary pain, cheilitis, cholecystitis, cholelithiasis, esophageal spasms, duodenitis, hematemesis, gastroesophageal reflux disease, gastrointestinal hemorrhage, gum hemorrhage, hepatitis, ileitis, jaundice, intestinal obstruction, liver tenderness, parotitis, periodontitis, proctitis, rectal disorder, salivary gland enlargement, increased salivation, soft stools, tongue discoloration. Endocrine system - Rare: galactorrhoea, goiter, hyperthyroidism, hypothyroidism, thyroid nodule, thyroiditis. Hemic and lymphatic system Frequent: ecchymosis; Infrequent: anemia, leukocytosis, leukopenia, lymphadenopathy, thrombocythemia; Rare: basophilia, bleeding time increased, cyanosis, eosinophilia, lymphocytosis, multiple myeloma, purpura, thrombocytopenia. Metabolic and nutritional - Frequent: edema, weight gain; Infrequent: alkaline phosphatase increased, dehydration, hypercholesteremia, hyperglycemia, hyperlipidemia, hypokalemia, SGOT increased, SGPT increased, thirst; Rare: alcohol intolerance, bilirubinemia, BUN increased, creatinine increased, diabetes mellitus, glycosuria, gout, healing abnormal, hemochromatosis, hypercalcinuria, hyperkalemia, hyperphosphatemia, hyperuricemia, hypocholesteremia, hypoglycemia, hyponatremia, hypophosphatemia, hypoproteinemia, uremia. Musculoskeletal system - Infrequent: arthritis, arthrosis, bone spurs, bursitis, leg cramps, myasthenia, tenosynovitis; Rare: bone pain, pathological fracture, muscle cramp, muscle spasms, musculoskeletal stiffness, myopathy, osteoporosis, osteosclerosis, plantar fasciitis, rheumatoid arthritis, tendon rupture. Nervous system - Frequent: amnesia, confusion, depersonalization, hypesthesia, thinking abnormal, trismus, vertigo; Infrequent: akathisia, apathy, ataxia, circumoral paresthesia, CNS stimulation, emotional lability, euphoria, hallucinations, hostility, hyperesthesia, hyperkinesia, hypotonia, incoordination, libido increased, manic reaction, myoclonus, neuralgia, neuropathy, psychosis, seizure, abnormal speech, stupor, suicidal ideation; Rare: abnormal/changed behavior, adjustment disorder, akinesia, alcohol abuse, aphasia, bradykinesia, buccoglossal syndrome, cerebrovascular accident, feeling drunk, loss of consciousness, delusions, dementia, dystonia, energy increased, facial paralysis, abnormal gait, Guillain-Barré syndrome, homicidal ideation, hyperchlorhydria, hypokinesia, hysteria, impulse control difficulties, motion sickness, neuritis, nystagmus, paranoid reaction, paresis, psychotic depression, reflexes decreased, reflexes increased, torticollis. Respiratory system - Frequent: cough increased, dyspnea; Infrequent: asthma, chest congestion, epistaxis, hyperventilation, laryngismus, laryngitis, pneumonia, voice alteration; Rare: atelectasis, hemoptysis, hypoventilation, hypoxia, larynx edema, pleurisy, pulmonary embolus, sleep apnea. Skin and appendages - Frequent: pruritus; Infrequent: acne, alopecia, contact dermatitis, dry skin, eczema, maculopapular rash, psoriasis, urticaria; Rare: brittle nails, erythema nodosum, exfoliative dermatitis, lichenoid dermatitis, hair discoloration, skin discoloration, furunculosis, hirsutism, leukoderma, miliaria, petechial rash, pruritic rash, pustular rash, v esiculobullous rash, seborrhea, skin atrophy, skin hypertrophy, skin striae, sweating decreased. Special senses - Frequent: abnormality of accommodation, mydriasis, taste perversion; Infrequent: conjunctivitis, diplopia, dry eyes, eye pain, otitis media, parosmia, photophobia, taste loss; Rare: blepharitis, cataract, chromatopsia, conjunctival edema, corneal lesion, deafness, exophthalmos, eye hemorrhage, glaucoma, retinal hemorrhage, subconjunctival hemorrhage, hyperacusis, keratitis, labyrinthitis, miosis, papilledema, decreased pupillary reflex, otitis externa, scleritis, uveitis, visual field defect. Urogenital system - Frequent: albuminuria, urination impaired; Infrequent: amenorrhea, cystitis, dysuria, hematuria, kidney calculus, kidney pain, leukorrhea, menorrhagia, metrorrhagia, nocturia, breast pain, polyuria, pyuria, prostatic disorder (prostatitis, enlarged prostate, and prostate irritability), urinary incontinence, urinary retention, urinary urgency, vaginal hemorrhage, vaginitis; Rare: abortion, anuria, balanitis, bladder pain, breast discharge, breast engorgement, breast enlargement, endometriosis, female lactation, fibrocystic breast, calcium crystalluria, cervicitis, orchitis, ovarian cyst, prolonged erection, gynecomastia (male), hypomenorrhea, kidney function abnormal, mastitis, menopause, pyelonephritis, oliguria, salpingitis, urolithiasis, uterine hemorrhage, uterine spasm, vaginal dryness. Postmarketing Reports: agranulocytosis, anaphylaxis, aplastic anemia, catatonia, congenital anomalies, CPK increased, deep vein thrombophlebitis, delirium, EKG abnormalities such as QT prolongation; cardiac arrhythmias including atrial fibrillation, supraventricular tachycardia, ventricular extrasystoles, and rare reports of ventricular fibrillation and ventricular tachycardia, including torsa http://www.wyeth.com
Table of Contents Feed for the Digital Edition of Managed Care - September 2008 Managed Care - September 2008 Editor’s Memo Contents Legislation & Regulation News and Commentary Medication Management Compensation Monitor Archimedes Lends Hippocrates a Hand Some Other Predictive Modeling Programs Messing With Medicare Advantage The Trouble With MAC MedPAC’s Suggestions Sound Familiar The Leader in Patient Satisfaction Formulary Files Plan Watch Tomorrow’s Medicine Ad Index Outlook Managed Care - September 2008 Managed Care - September 2008 - Managed Care - September 2008 (Page Cover1) Managed Care - September 2008 - Managed Care - September 2008 (Page Cover2) Managed Care - September 2008 - Managed Care - September 2008 (Page Cover3) Managed Care - September 2008 - Managed Care - September 2008 (Page Cover4) Managed Care - September 2008 - Editor’s Memo (Page 1) Managed Care - September 2008 - Contents (Page 2) Managed Care - September 2008 - Contents (Page 3) Managed Care - September 2008 - Contents (Page 4) Managed Care - September 2008 - Legislation & Regulation (Page 5) Managed Care - September 2008 - Legislation & Regulation (Page 6) Managed Care - September 2008 - News and Commentary (Page 7) Managed Care - September 2008 - News and Commentary (Page 8) Managed Care - September 2008 - News and Commentary (Page 9) Managed Care - September 2008 - Medication Management (Page 10) Managed Care - September 2008 - Medication Management (Page 11) Managed Care - September 2008 - Medication Management (Page 12) Managed Care - September 2008 - Compensation Monitor (Page 13) Managed Care - September 2008 - Archimedes Lends Hippocrates a Hand (Page 14) Managed Care - September 2008 - Archimedes Lends Hippocrates a Hand (Page 15) Managed Care - September 2008 - Archimedes Lends Hippocrates a Hand (Page 16) Managed Care - September 2008 - Archimedes Lends Hippocrates a Hand (Page 17) Managed Care - September 2008 - Archimedes Lends Hippocrates a Hand (Page 18) Managed Care - September 2008 - Archimedes Lends Hippocrates a Hand (Page 19) Managed Care - September 2008 - Some Other Predictive Modeling Programs (Page 20) Managed Care - September 2008 - Some Other Predictive Modeling Programs (Page 21) Managed Care - September 2008 - Some Other Predictive Modeling Programs (Page 22) Managed Care - September 2008 - Some Other Predictive Modeling Programs (Page 23) Managed Care - September 2008 - Messing With Medicare Advantage (Page 24) Managed Care - September 2008 - Messing With Medicare Advantage (Page 25) Managed Care - September 2008 - Messing With Medicare Advantage (Page 26) Managed Care - September 2008 - Messing With Medicare Advantage (Page 27) Managed Care - September 2008 - Messing With Medicare Advantage (Page 28) Managed Care - September 2008 - Messing With Medicare Advantage (Page 29) Managed Care - September 2008 - The Trouble With MAC (Page 30) Managed Care - September 2008 - The Trouble With MAC (Page 31) Managed Care - September 2008 - The Trouble With MAC (Page 32) Managed Care - September 2008 - The Trouble With MAC (Page 33) Managed Care - September 2008 - The Trouble With MAC (Page 34) Managed Care - September 2008 - The Trouble With MAC (Page 35) Managed Care - September 2008 - The Trouble With MAC (Page 36) Managed Care - September 2008 - MedPAC’s Suggestions Sound Familiar (Page 37) Managed Care - September 2008 - MedPAC’s Suggestions Sound Familiar (Page 38) Managed Care - September 2008 - MedPAC’s Suggestions Sound Familiar (Page 39) Managed Care - September 2008 - MedPAC’s Suggestions Sound Familiar (Page 40) Managed Care - September 2008 - The Leader in Patient Satisfaction (Page 41) Managed Care - September 2008 - The Leader in Patient Satisfaction (Page 42) Managed Care - September 2008 - The Leader in Patient Satisfaction (Page 43) Managed Care - September 2008 - The Leader in Patient Satisfaction (Page 44) Managed Care - September 2008 - The Leader in Patient Satisfaction (Page 45) Managed Care - September 2008 - The Leader in Patient Satisfaction (Page 46) Managed Care - September 2008 - Formulary Files (Page 47) Managed Care - September 2008 - Plan Watch (Page 48) Managed Care - September 2008 - Plan Watch (Page 49) Managed Care - September 2008 - Tomorrow’s Medicine (Page 50) Managed Care - September 2008 - Ad Index (Page 51) Managed Care - September 2008 - Outlook (Page 52) Managed Care - September 2008 - Outlook (Page C1) Managed Care - September 2008 - Outlook (Page C2) Managed Care - September 2008 - Outlook (Page C3) Managed Care - September 2008 - Outlook (Page C4) Managed Care - September 2008 - Outlook (Page C5) Managed Care - September 2008 - Outlook (Page C6) Managed Care - September 2008 - Outlook (Page C7) Managed Care - September 2008 - Outlook (Page C8) Managed Care - September 2008 - Outlook (Page C9) Managed Care - September 2008 - Outlook (Page C10) Managed Care - September 2008 - Outlook (Page C11) Managed Care - September 2008 - Outlook (Page C12) Managed Care - September 2008 - Outlook (Page C13) Managed Care - September 2008 - Outlook (Page C14) Managed Care - September 2008 - Outlook (Page C15) Managed Care - September 2008 - Outlook (Page C16) Managed Care - September 2008 - Outlook (Page C17)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.